Search

Your search keyword '"Imamura, Tomoaki"' showing total 14 results
Start Over Author "Imamura, Tomoaki" Publisher wiley
14 results on '"Imamura, Tomoaki"'

1. The impact of hospital case volume on the outcomes after catheter ablation for atrial fibrillation according to the ablation technology

Author

Kanaoka, Koshiro, primary, Nishida, Taku, additional, Nishioka, Yuichi, additional, Myojin, Tomoya, additional, Kubo, Shinichiro, additional, Soeda, Tsunenari, additional, Okada, Katsuki, additional, Noda, Tatsuya, additional, Iwanaga, Yoshitaka, additional, Miyamoto, Yoshihiro, additional, Sakata, Yasushi, additional, Imamura, Tomoaki, additional, and Saito, Yoshihiko, additional

Published
2022
Full Text
View/download PDF

3. Association between dipeptidyl peptidase‐4 inhibitors and increased risk for bullous pemphigoid within 3 months from first use: A 5‐year population‐based cohort study using the Japanese National Database

Author

Kuwata, Hirohito, primary, Nishioka, Yuichi, additional, Noda, Tatsuya, additional, Kubo, Shinichiro, additional, Myojin, Tomoya, additional, Higashino, Tsuneyuki, additional, Takahashi, Yutaka, additional, Ishii, Hitoshi, additional, and Imamura, Tomoaki, additional

Published
2021
Full Text
View/download PDF

14. Contemporary Use of β-Blockers in Heart Failure Patients With and Without Atrial Fibrillation: A Nationwide Database Analysis.

Author

Nakai M, Iwanaga Y, Kanaoka K, Sumita Y, Nishioka Y, Myojin T, Okada K, Noda T, Imamura T, and Miyamoto Y

Abstract

Evidence of the effectiveness of β-blockers in heart failure (HF) and atrial fibrillation (AF) in a contemporary cohort is controversial. This study investigated the association between the use of β-blockers and prognosis in hospitalized HF patients with and without AF in Japan. Patients hospitalized with the first episode of acute HF were identified from the National Database of Health Insurance Claims and Specific Health Checkups of Japan between April 2014 and March 2021. Associations of β-blocker use and prognosis were compared by propensity score matching among the AF or non-AF group. A mixed-effects survival model was used, and hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Among 428,650 patients discharged with HF in 4,433 hospitals, 175,174 (40.9%) were ≥ 85 years old, 151,873 (35.4%) had complicated AF, and 236,457 (55.2%) were β-blocker users. In a matched AF group, β-blocker use was associated with a lower composite outcome of all-cause mortality or HF rehospitalization (HR [95% CI], 0.95 [0.93-0.97]). A similar result was obtained in a matched non-AF group (0.95 [0.94-0.96]). In addition, the HRs in patients aged ≥ 85 years and female patients were 1.00 [0.98-1.02] and 1.01 [0.98-1.03] in the AF group and 1.03 [1.01-1.05] and 0.98 [0.97-1.00] in the non-AF group, respectively. The favorable prognostic associations of β-blocker use were observed regardless of AF in patients across a broad spectrum of HF in a superaged society., (© 2024 The Author(s). Clinical Pharmacology & Therapeutics © 2024 American Society for Clinical Pharmacology and Therapeutics.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results